Apply Now

Summary

The Editor-in-Chief of the Journal of Vascular Surgery Cases, Innovations and Techniques (JVS-CIT) requests applications for the Associate Editor/Social Media Editor position. Prior service on the Editorial Board of the JVS-CIT or other JVS publications is preferable but not required. The individual must be an Active or Senior Member of the Society for Vascular Surgery (SVS). The criteria for selection for this position also include evidence of scholarly activity through peer-reviewing and publishing. Additionally, applicants for this role should demonstrate interest in Social Media and its application in academic publishing.

Key Responsibilities

In this role, Editors will act on approximately 200 submissions a year, which includes assigning reviewers, evaluating the reviews, communicating with authors, evaluating authors' responses, and making recommendations to the editor-in-chief on final manuscript publication. Applicants must also be able to attend regular virtual editorial meetings with journal staff and editors. Additional Social Media duties include:

• handling the JVS-CIT social media accounts,
• regular collaboration with the other JVS social media editors and SVS/Elsevier marketing teams, and
• developing new promotional campaigns for the journal.

The JVS-CIT values and supports diversity, equity, and inclusion (DEI) for all editorial board opportunities. We encourage enthusiastic, eligible applicants, regardless of gender, age, sexual orientation, ethnicity or race, to apply. An annual financial stipend is provided for these positions. The term of the appointment is three years and will commence on July 1st, 2025.

Conflict of Interest

Per the SVS Policy on Conflict, JVS editors may have no direct financial relationships with Industry during their terms of service.

Application Process

To apply, please submit a brief statement of interest, including your previous relevant experience and qualifications (350 words) via the SVS application site and submit your CV by email to jvascsurg@vascularsociety.org.

Apply Now

Summary

The Society for Vascular Surgery (SVS) seeks a new editor-in-chief (EIC) for its flagship journal, the Journal of Vascular Surgery (JVS). The JVS is the premier international journal of medical, endovascular, and surgical care of vascular diseases. It is a hybrid subscription and open-access monthly publication that receives close to 2,000 submissions annually.

The SVS Executive Board appoints the EIC, who is responsible for the academic and editorial quality of the JVS. The EIC will collaborate closely with the senior managing editor, the publisher, the executive editor of the JVS journals, the companion journals EICs, and the SVS director of publications.

The successful candidate is expected to start their editorial tenure on July 1, 2025, and receive transitional support from the editorial leadership group, including Executive Editor Dr. Ronald Dalman and current JVS EIC Dr. Thomas Forbes. The initial term will be four years, with the possibility of renewal for an additional two years, dependent on EIC interest and the recommendation of the Publications Committee.

Key Responsibilities

• Oversee the academic quality of the JVS, ensuring that JVS content is accurate, credible, authoritative, and relevant to the journal’s scope and mission.
• With support from the senior managing editor, determine and regularly evaluate progress on key performance indicators and set performance targets for the JVS.
• Approve all materials for publication in JVS, including articles, commentaries, editorials, reviews, and advertising. All editorial decisions—except when the EIC is conflicted—are finally made by the EIC.
• Determine the lineup for each issue of the journal and, along with the senior managing editor, review the issue proofs prior to publication.
• Appoint and oversee JVS associate editors and the members of the JVS Editorial Board.
• Participate in the selection process for open EIC positions at other JVS journals.
• Collaborate with other portfolio EICs to coordinate internal transfer offers for submissions not of interest to the JVS.
• Establish procedures to help maintain journal quality, identify errors and problems, detect trends that reflect quality deterioration, and, in collaboration with the publisher, implement corrective actions as needed.
• Conduct at least one Editorial Board meeting annually, during which the EIC will provide the Editorial Board with an update on the Journal, identify and discuss areas needing performance improvement, and explore opportunities for editorial development and potential enhancements to the print and online Journal.
• Act professionally, without prejudice or conflict of interest. The EIC must divest from all commercial stakes and interests that might impact, or be perceived to impact, their ability to make objective decisions on behalf of the JVS.
• Provide regular updates to the Publications Committee on JVS performance and initiatives in collaboration with the executive editor.
• Meet regularly with the companion journal EICs and the executive editor to maintain awareness of issues and initiatives across the portfolio, discuss best practices, and support optimal coordination and collaboration.
• Develop and execute a strategic plan for the JVS, collaborating with the executive editor and director of publications.

Time & Travel Commitment

On average, the expectation is that the JVS EIC will spend 12-20 hours per week on JVS responsibilities. This includes daily engagement with the editorial review and decision workflow in Editorial Manager, including processing new submissions (by deciding to desk reject, to send for peer review, or to assign to an associate editor for handling), reviewing completed peer reviews for manuscripts ready for an editorial decision, or reviewing and finalizing the editorial decisions of associate editors. In addition, the EIC meets regularly with both the JVS editor group (biweekly meetings) and the editorial leadership of the portfolio (monthly meetings), along with ad hoc calls with the executive editor, SVS journals staff, and other stakeholders on an as-needed basis. While most of the EIC responsibilities are carried out remotely, the EIC is expected to attend the VAM each year and the annual one-day EIC retreat at SVS headquarters each fall. 

Conflicts of Interest

Per the SVS Policy on Conflict, JVS editors may have no direct financial relationships with industry during their terms of service. A direct financial relationship is a compensated relationship that should generate an IRS Form W-2, 1099, or equivalent income report. If the successful applicant currently has direct financial relationships with industry, these relationships must be terminated within six months of appointment. NB: JVS editors may accept research support as long as monies are paid to the institution where the research is conducted, not to the individual. Nevertheless, in all cases, research support, uncompensated services, and other permitted relationships must be disclosed to the SVS. The EIC should not have editorial leadership positions with other journals.

Application Process

Applicants must complete the online application form and share their current curriculum vitae for the Search Committee’s review. Please send your CV to Phil Jackson, SVS staff liaison to the Search Committee.

SVS is committed to a fair and inclusive selection process and values the contributions of diverse perspectives and experiences to the health of our scholarly journals and our Society. We encourage qualified applicants of all backgrounds to apply.

Application deadline: Aug. 14, 2024

Apply Now

The editor-in-chief of the Journal of Vascular Surgery Cases, Innovations and Techniques (JVS-CIT) requests applications for the following position:

Associate Editor/DEI Officer

Prior service on the Editorial Board of the JVS-CIT or other JVS publications is preferable but not required. The individual must be an Active or Senior Member of the Society for Vascular Surgery (SVS). The criteria for selection for this position also include evidence of scholarly activity through peer-reviewing and publishing. Editors will act on approximately 200 submissions a year, which includes assigning reviewers, evaluating the reviews, communicating with authors, evaluating authors' responses and making recommendations to the editor-in-chief on final manuscript publication. Applicants should also have an interest in Diversity, Equity and Inclusion (DEI) as applied to academic publishing.

The JVS-CIT values and supports DEI for all editorial board opportunities. We encourage enthusiastic, eligible applicants, regardless of gender, age, sexual orientation, ethnicity or race, to apply.

Per the SVS Policy on Conflict, JVS editors may have no direct financial relationships with Industry during their terms of service.

An annual financial stipend is provided for these positions. The term of the appointment is 3 years and will commence on Sept. 1, 2024. 

To apply, please submit a brief statement of interest including your previous relevant experience and qualifications (350 words) via the SVS application site and submit your CV by email to jvascsurg@vascularsociety.org.

The History of the SVS Foundation

“Which of the operations we are doing today will be the discards of the next decade? What is needed is knowledge and such knowledge will be provided by the young amongst us and those yet to come.” – Allan Callow, 1987

The Beginning … 1984

The idea for the creation of a charitable foundation for the promotion of research came about at the 1984 the Society for Vascular Surgery (SVS) Council meeting. Dr. Allan Callow requested the “Council’s consideration for the utilization of certain assets of the Society to further the interests of young surgeons in the specialty of vascular surgery.”

In the early 1980s, vascular  surgeons had become experts in the surgical treatment of atherosclerosis obliterans. However, fundamental knowledge about the atherosclerosis obliterans and fundamental insights into the pathogenesis of neointimal hyperplasia were lacking. Vascular surgical research generally consisted of implanting prosthetic devices in the arterial system and studying patency. Vascular surgeons were only beginning to investigate the basic biologic mechanisms utilizing cell and molecular technology.

Unfortunately, funding for research at the time was difficult and discouraged many young investigators. National Institutes of Health (NIH) funding of grants was low, particularly for surgeons. In 1982 departments of surgery received only 5.1 percent of the total research allotment of the NIH and funding was declining. It also became apparent to SVS leaders that, with the rapid expansion of biologic investigations, dabbling in basic science research was no longer possible. Basic science required substantial commitment by young investigative clinician/scientists to compete with non‐surgical colleagues. The SVS recognized the time commitment needed for career development and the financial resources required in the establishment of the foundation.

June 1986

The SVS Board approved the Education/Research Foundation at the Council meeting. The new foundation’s board of directors met in New Orleans on October 22, 1986. The first board members included Vic Bernhardt, Allan Callow, Cal Ernst, Wesley Moore and Malcolm Perry. At this first meeting, officers were elected: Cal Ernst, president; Vic Bernhardt, vice president; and Malcolm Perry, secretary/treasurer. The foundation’s financial support was a grant of $50,000 from SVS; W. L. Gore, $10,000; and contributions from board of directors’ members, $4,000.

Mid‐1980s

Dr. Gene Strandness established the first Research Initiatives Conference in conjunction with the NIH and the National Heart, Lung, and Blood Institute (NHLBI). Dr. Strandness had served on the NHLBI Cardiology Advisory Committee and developed a relationship with Dr. John Watson, the chief of the Devices and Technology Branch. Together they envisioned a workshop to bring together vascular surgeons and members of the NIH to attract the best scientific minds available in the research community to serve as an incubator for ideas. The first meeting resulted in a book entitled Vascular Diseases: Current Research and Clinical Applications published in1987. The first meeting of the Research Initiatives programs was held February 19‐20, 1988 in Bethesda, MD. This was jointly sponsored by SVS and the North American Chapter, International Society for Cardiovascular Surgery (NA-ISCVS).

1988

Dr. Michael DeBakey became foundation president and the foundation was registered in Illinois as a legal entity.

1989

The Foundation for Research and Education adopted a new name: The Lifeline Foundation. The SVS leadership and the Lifeline Foundation leadership asked the SVS council for $100,000 annually for five years to establish funding for the first award. The foundation leaders included Drs. Michael DeBakey, Thomas Fogarty, Robert Leather, John Mannick, John Ochsner, Ronald Stoney, Vic Bernhardt, Malcom Perry, Allan Callow, Wesley Moore, and E. Stanley Crawford.

1991

Dr. Cal Ernst served as an executive director of the foundation for five years, creating programs such as the Industrial Advisory Committee (IAC) and the first award of $50,000 for two years. The first grant awarded was presented to Brian Rubin, Washington University, to study the effects of the duration of thrombosis on vessel wall thrombogenicity. The IAC, which was created at the suggestion of Dr. Ron Stoney, allowed industry participation in the foundation and provided a closer liaison between the two groups.

1991‐1994

Dr. Ron Stoney was the foundation’s executive director with support from Joe Stone, executive director of PRRI Management Firm. In 1994 the Lifeline Foundation’s mission was formalized to support research and education in vascular disease by 1) enhancing the development of young surgical scientists in the advancement of vascular science through its comprehensive research funding commitment; and 2) insuring that new knowledge concerning the cause, treatment, and prevention of vascular disease is disseminated to the medical profession and the public. To this end, the board of directors with the Joint Council established a research forum at the annual joint meeting in 1994 with more than 150 abstracts being submitted. The board was expanded to include members from industry and the lay public.

1992

The NA-ISCVS Council agreed to match support from the SVS of $100,000 for five years for equal representation in the Lifeline Foundation. The inclusion of ISCVS increased the board of directors’ membership to include representation from the ISCVS and was associated with the transfer of the Student Fellowship Research Award to the Foundation.

1993

By 1993 the foundation was ready to fund the second award, which was given to Dr. Colleen Brophy to study the molecular model of vasospasm. During the summer of 1993 the Lifeline Foundation officers requested support from the regional societies. The regional societies were supportive and provided funds ranging from $10,000 to $50,000.

1996‐1997

Dr. John Mannick was the Lifeline Foundation president. During the first year of his leadership, the foundation was restructured to make it more responsive to the needs of its constituencies. Four new members from industry were added; all had voting privileges on the foundation. In addition, Dr. James Yao was asked to serve as the vice president for development, and liaisons from the NHLBI, David Robinson, and for clinical investigations, Dr. Rod White, were added.

1997

The Endoluminal Graft Registry project was begun and was led by Dr. White. The Endoluminal Graft Registry recruited funding for a robust project to evaluate FDA‐approved endovascular devices. The Endovascular Registry reports were publicized in Journal for Vascular Surgery (J Vasc Surg 2005;42:1‐10).

1997‐1998

Dr. Alex Clowes, along with Dr. Mannick, approached the NIH for co‐sponsorship of the KO8 grant. This was a landmark event for the foundation and vascular surgery. For the first time the  NIH partnered with a society for sponsorship of a KO8 grant. The KO8 mechanism funded early career development of vascular surgeons/scientists. During this same interval Dr. Mannick proposed to the William von Liebig Foundation funding of these KO8 grants. Working with Linda Hamilton of the von Liebig Foundation, a memorandum of understanding was completed and signed in November 1998. At the same time, an anonymous donor provided $1 million in support for endowing clinical research grants. Dr. James Yao began an aggressive program of the membership, the regional societies, and industries for matching awards. The details of the endowment were that a corpus of $3 million was required before interest could be spent on funding awards.

1999

Dr. Julius Jacobson and his family provided an endowment that supports the Research Initiatives program.

The first year of availability for the KO8‐von Liebig awards was July 1, 1999. During that year six applications were made for the grant and the first awardees were Dr. Michael Conte of Brigham and Women’s Hospital, Harvard Medical School, for a project entitled “Genetic Engineering of Failure‐Resistant Vein Graft” and Dr. Larry Kraiss of the University of Utah School of Medicine for his project entitled “Control of Endothelial Translation by Fluid Sheer Stresses.” As a result of the success with the NHLBI/Lifeline Foundation/von Liebig Foundation awards, discussions occurred at the Medical Research Council of Canada to allow the development of a similar program.

2000

Dr. Julius Jacobson provided $500,000 for Research Initiatives Program support.

March 2002

Requests for clinical research applications were accepted for the first funding by the K23 grant.

2003‐2004

The SVS and AAVS (NA-ISCVS) merged to form the SVS and the process began to also merge both organizations’ foundations. The SVS’ Lifeline Foundation merged with the AAVS’ American Vascular Association (AVA) and continued operations under the AVA banner. The new foundation continued to support the research mission work of the Lifeline Foundation and the vascular disease awareness programs of the previous American Vascular Association which included a National Screening Program.

2010‐2011

The SVS leadership and AVA board agreed that the name of the foundation should be changed to the SVS Foundation to clearly brand the foundation as the charitable arm of the SVS. A restructuring of the foundation occurred, with a majority of the SVS officers also serving as foundation leadership. The scope of the foundation’s mission was narrowed to focus on providing research support.

2016

The SVS Foundation leadership recommended that the scope of the mission be expanded to include vascular disease awareness and prevention in addition to its core mission of research. (Source of 1984‐2002 information: SVS Foundation 20th anniversary promotion).

For more on the original AVA and Lifeline Foundation, follow this link to a Journal of Vascular Surgery article published in 2008.

AVA \  LIFELINE FOUNDATION 20TH ANNIVERSARY